Sandoz's approval of Afqlir highlights their commitment to affordable, effective treatment options for retinal diseases.

Evaluation of luciferase and prefusion-stability F protein from respiratory syncytial virus mRNA/LNPs in pre-clinical models using jet delivery compared to needle and syringe ... in mRNA technologies ...

Afqlir is indicated to treat various retinal diseases, including neovascular age-related macular degeneration (nAMD) ...

MEDIA RELEASE Afqlir® (aflibercept) approved to treat various retinal diseases, including neovascular age-related macular degeneration (nAMD)One of several biosimilar value drivers for SandozSandoz ...

China realized the long-term cultivation of vertebrates in the space station, said Sun Yonghua, a researcher of the IHB, ...

The new line, with its capability to handle multiple syringe sizes (1 ml, 2.25 ml ... at the Gerontological Society of America Annual Scientific Meeting 2024 Epirium Bio, Inc. (Epirium), a ...

Yes, Bill’s commitment remains aligned with our priority areas. Each year, the foundation allocates around $8.4 billion ...

Kamen and Sequel Medtech CEO Alan Lotvin say they are offering greater precision in insulin delivery with new pump technology ...

This will include considerations such as scientific rationale and reasons to believe our ... also included our product ...

Health authorities say they are continuing to manage the shortage and supply of IV fluids as a priority. Doctors are fighting ...